• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesCurrent TOCInstructions for authors
Ann Rheum Dis. Sep 2003; 62(9): 825–828.
PMCID: PMC1754647

Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis

Abstract

Objectives: To investigate the biodistribution and specific targeting for tumour necrosis factor (TNF) of a fully human, radiolabelled anti-TNF monoclonal antibody (anti-TNF mAb) in patients with active rheumatoid arthritis (RA). To assess whether this agent is suitable for visualisation of synovitis.

Methods: Ten patients with RA underwent whole body scintigraphy after administration of a tracer—subtherapeutic dose of 100 µg 99mTc human anti-TNF mAb. After two weeks, the procedure was repeated to assess the specificity of the radiolabelled antibody for TNF and its sensitivity for changes in inflammation. Therefore, a competition study was performed in five patients, who received excess unlabelled anti-TNF mAb before the tracer dose of 99mTc-anti-TNF. Another five patients received 120 mg methylprednisolone two days before the second scintigraphy.

Results: Radiolabelled anti-TNF mAb allowed clear visualisation of inflamed joints in patients with active RA with a high specificity. Concomitant administration of excess unlabelled anti-TNF reduced the joint uptake of 99mTc-anti-TNF mAb by a median of 25% as a percentage of the injected dose after 24 hours, whereas uptake in liver and spleen remained unchanged. Systemic corticosteroids reduced the disease activity, which was mirrored by a decreased joint uptake of the tracer. The anti-TNF mAb retained its high affinity for TNFα after labelling and was cleared from the circulation with an elimination half life of 48 hours. The procedure was well tolerated.

Conclusions: Radiolabelled human anti-TNF mAb allows visualisation of synovitis in patients with RA. Joint accumulation of this agent is partly due to specific TNF targeting and is highly predictive for inflammation.

Full Text

The Full Text of this article is available as a PDF (81K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Deleuran BW, Chu CQ, Field M, Brennan FM, Mitchell T, Feldmann M, Maini RN. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum. 1992 Oct;35(10):1170–1178. [PubMed]
  • Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991 Sep;34(9):1125–1132. [PubMed]
  • Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis. 2001 Jul;60(7):660–669. [PMC free article] [PubMed]
  • Ulfgren AK, Gröndal L, Lindblad S, Khademi M, Johnell O, Klareskog L, Andersson U. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis. 2000 Jun;59(6):439–447. [PMC free article] [PubMed]
  • van der Laken CJ, Boerman OC, Oyen WJ, van de Ven MT, van der Meer JW, Corstens FH. Imaging of infection in rabbits with radioiodinated interleukin-1 (alpha and beta), its receptor antagonist and a chemotactic peptide: a comparative study. Eur J Nucl Med. 1998 Apr;25(4):347–352. [PubMed]
  • Van der Laken CJ, Boerman OC, Oyen WJ, Van de Ven MT, Ven der Meer JW, Corstens FH. The kinetics of radiolabelled interleukin-8 in infection and sterile inflammation. Nucl Med Commun. 1998 Mar;19(3):271–281. [PubMed]
  • Chapman PT, Jamar F, Keelan ET, Peters AM, Haskard DO. Use of a radiolabeled monoclonal antibody against E-selectin for imaging of endothelial activation in rheumatoid arthritis. Arthritis Rheum. 1996 Aug;39(8):1371–1375. [PubMed]
  • Jamar F, Chapman PT, Manicourt DH, Glass DM, Haskard DO, Peters AM. A comparison between 111In-anti-E-selectin mAb and 99Tcm-labelled human non-specific immunoglobulin in radionuclide imaging of rheumatoid arthritis. Br J Radiol. 1997 May;70(833):473–481. [PubMed]
  • Steffens MG, Oosterwijk E, Kranenborg MH, Manders JM, Debruyne FM, Corstens FH, Boerman OC. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations. J Nucl Med. 1999 May;40(5):829–836. [PubMed]
  • Santora LC, Krull IS, Grant K. Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. Anal Biochem. 1999 Nov 1;275(1):98–108. [PubMed]
  • Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis. 2002 Nov;61 (Suppl 2):ii70–ii73. [PMC free article] [PubMed]
  • Kempeni J. Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody. Ann Rheum Dis. 2000 Nov;59 (Suppl 1):i44–i45. [PMC free article] [PubMed]
  • den Broeder AA, Joosten LAB, Saxne T, Heinegård D, Fenner H, Miltenburg AMM, Frasa WLH, van Tits LJ, Buurman WA, van Riel PLCM, et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis. 2002 Apr;61(4):311–318. [PMC free article] [PubMed]
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. [PubMed]
  • van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990 Nov;49(11):916–920. [PMC free article] [PubMed]
  • Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, Fuccello AJ, Rubin RH, Strauss HW, Fischman AJ. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 1990 Dec;31(12):2022–2028. [PubMed]
  • Hnatowich DJ, Qu T, Chang F, Ley AC, Ladner RC, Rusckowski M. Labeling peptides with technetium-99m using a bifunctional chelator of a N-hydroxysuccinimide ester of mercaptoacetyltriglycine. J Nucl Med. 1998 Jan;39(1):56–64. [PubMed]
  • Dams ET, Oyen WJ, Boerman OC, Claessens RA, Wymenga AB, van der Meer JW, Corstens FH. Technetium-99m labeled to human immunoglobulin G through the nicotinyl hydrazine derivative: a clinical study. J Nucl Med. 1998 Jan;39(1):119–124. [PubMed]
  • Buijs WC, Oyen WJ, Dams ET, Boerman OC, Siegel JA, Claessens RA, van der Meer JW, Corstens FH. Dynamic distribution and dosimetric evaluation of human non-specific immunoglobulin G labelled with 111In or 99Tcm. Nucl Med Commun. 1998 Aug;19(8):743–751. [PubMed]
  • Oyen WJ, Boerman OC, van der Laken CJ, Claessens RA, van der Meer JW, Corstens FH. The uptake mechanisms of inflammation- and infection-localizing agents. Eur J Nucl Med. 1996 Apr;23(4):459–465. [PubMed]
  • van der Laken CJ, Boerman OC, Oyen WJ, van de Ven MT, van der Meer JW, Corstens FH. Scintigraphic detection of infection and inflammation: new developments with special emphasis on receptor interaction. Eur J Nucl Med. 1998 May;25(5):535–546. [PubMed]

Figures and Tables

Figure 1
Scintigraphic images of the whole body and hands of a patient with active RA after injection of 99mTc human anti-TNF mAb. (A) The first imaging session. (B) Decreased uptake in joints after administration of an excess unlabelled anti-TNF mAb (hands detail), ...
Figure 2
Course of the DAS during the study. Patients with active RA underwent a first scintigraphy with a tracer dose of a fully human anti-TNF mAb radiolabelled with 99mTc. Two weeks thereafter, a subset of patients (n=5, rhomboids) received a therapeutic dose ...

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...